Theralase Technologies (CVE:TLT) Stock Price Up 1.8% – Here’s Why

Theralase Technologies Inc. (CVE:TLT)’s share price rose 1.8% during trading on Friday . The stock traded as high as C$0.30 and last traded at C$0.29. Approximately 191,650 shares traded hands during trading, a decline of 15% from the average daily volume of 226,799 shares. The stock had previously closed at C$0.28.

Theralase Technologies Trading Up 1.8%

The company has a fifty day simple moving average of C$0.25 and a two-hundred day simple moving average of C$0.21. The company has a market capitalization of C$75.50 million, a P/E ratio of -15.83 and a beta of -0.13. The company has a debt-to-equity ratio of 14.85, a current ratio of 1.91 and a quick ratio of 3.40.

Theralase Technologies Company Profile

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.